Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2485095 | Journal of Pharmaceutical Sciences | 2010 | 11 Pages |
Abstract
The crystal structure determination of mebendazole form A, an anthelmintic drug, was performed for the first time by applying the DASH software program to synchrotron Xâray powder diffraction data, and supported by a satisfying Rietveld fit. This polymorph of mebendazole crystallizes in a triclinic (P1¯) space group, with unitâcell parameters aâ=â5.5044(2)âÃ
, bâ=â11.2872(2)âÃ
, câ=â12.5276(5)âÃ
, αâ=â66.694(2)°, βâ=â82.959(2)°, γâ=â78.443(2)°, Vâ=â699.52(5)âÃ
3, Zâ=â2, Mâ=â295.293âgâmolâ1, Ïcalcâ=â1.4021âgâcmâ3, and Ïmeasâ=â1.3935(66)âgâcmâ3, which were obtained by means of the unitâcell formula weight and a picnometric measurement, respectively. The goodnessâofâfit and Râfactors were, respectively: Ï2â=â1.746, RF2â=â1.69%, Rwpâ=â5.72%, and Rpâ=â4.37%. A weak nonclassical hydrogen bond involving the atoms N(3)H(23)â¯O(11) may be responsible for the greater stability of the polymorphic form A of mebendazole due to the strongest electronegativity of nitrogen. © 2009 WileyâLiss, Inc. and the American Pharmacists Association J Pharm Sci 99: 1734-1744, 2010
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Fabio Furlan Ferreira, Selma Gutierrez Antonio, Paulo César Pires Rosa, Carlos de Oliveira PaivaâSantos,